Abstract | OBJECTIVES: METHODS:
Quetiapine was administered to 16 consecutively enrolled stabilized patients with psychotic or mood disorders and tardive dystonia, replacing the "offending drugs," over a 3-month cross-tapering period. Target dose of quetiapine was set according to the defined daily dose of the received antipsychotic(s) at baseline, as reviewed by the World Health Organization Center of Drug Statistics Methodology, aiming at both maintenance of psychosis control and reduction of dystonic symptoms. RESULTS: Patients were found to have significant positive results in amelioration of dystonia (P < 0.001) over a 1-year period, without loss of antipsychotic efficacy. Reduction of dystonic symptoms with the use of quetiapine could be considered comparable with the positive effects of clozapine, with the additional advantage of relatively lacking serious side effects. CONCLUSIONS:
|
Authors | Philippos Gourzis, Maria Skokou, Evanthia Soubasi, Aggeliki Katrivanou, Panagiotis Polychronopoulos |
Journal | Clinical neuropharmacology
(Clin Neuropharmacol)
2015 Jul-Aug
Vol. 38
Issue 4
Pg. 121-6
ISSN: 1537-162X [Electronic] United States |
PMID | 26166233
(Publication Type: Journal Article)
|
Chemical References |
- Antipsychotic Agents
- Quetiapine Fumarate
- Clozapine
|
Topics |
- Adult
- Aged
- Antipsychotic Agents
(adverse effects)
- Clozapine
(adverse effects)
- Female
- Humans
- Male
- Middle Aged
- Movement Disorders
(complications, drug therapy, etiology)
- Quetiapine Fumarate
(therapeutic use)
- Retrospective Studies
- Sleep Wake Disorders
(drug therapy, etiology)
|